The T cell activating properties and antitumour activity of Staphylococcal Enterotoxin-like Q

  • Yanan He
  • Yuliang Sun
  • Yakun Ren
  • Liang Qiao
  • Rui Guo
  • Jiang Du
  • Xinxing ZhuEmail author
  • Yanli LiuEmail author
  • Juntang Lin
Original Investigation


Staphylococcal enterotoxins (SEs), as typical superantigens, exhibit promising antitumour activity in the clinic, but their unavoidable side effects related to fever and emesis seriously limit their application for the treatment of malignant tumours. Fortunately, the identification of Staphylococcal enterotoxin-like toxins (SEls), which possess amino acid sequences similar to those of classical SEs but exhibit no or low emetic activity, has provided a set of potential immunomodulatory candidates for cancer therapy. The aim of this study was to examine the effect of SElQ on lymphocyte activation and to further demonstrate its antitumour activity both in vitro and in vivo. High-purity SElQ was successfully harvested, and in vitro results confirmed that SElQ can significantly activate mouse- and human-derived lymphocytes in a dose-dependent manner, particularly CD4+ and CD8+ T cells, which showed significant increases in both percentage and absolute number. Further examination revealed that in addition to the originally recognized TCR Vβ5 and 21, TCR Vβ14, 17 and 18 were activated in SElQ-induced human PBMCs. Moreover, the expression of IL-2 and IFN-γ was significantly upregulated in vitro and in vivo after SElQ treatment. Based on the findings that SElQ induces lymphocyte activation and cytokine release, we then confirmed its antitumour activity both in vitro and in vivo. The data showed that treatment with a low concentration of SElQ (30 µg/mouse) could inhibit the growth of tumours by approximately 30% and no significant toxicity was observed. Taken together, our results demonstrated that SElQ can significantly induce T cell activation and cytokine release and further elicit substantial antitumour activity and thus provide support for the potential application of SElQ in cancer immunotherapy.


Immunotherapy Lymphocyte Staphylococcal enterotoxin Staphylococcal enterotoxin-like Q Superantigen 



The authors would like to thank all the teachers and students for their participation in this study.


This work was financially supported by the National Natural Science Foundation of China (No. 31502045) and Xinxiang Medical University Foundation (No. 2017CXY-2–12 and 20172DCG-03).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The peripheral blood samples used in this study were harvested with the informed consent of the donors, and the experimental procedures performed with the peripheral blood samples were approved by the Ethics Committee of Xinxiang Medical University. Furthermore, the mice handling and experimental procedures were performed with approval from the Animal Care Committee of Xinxiang Medical University in accordance with the guidelines established by the Chinese Council on Animal Care.

Supplementary material

430_2019_614_MOESM1_ESM.docx (1 mb)
Supplementary material 1 (DOCX 1032 kb)
430_2019_614_MOESM2_ESM.avi (896 kb)
Supplementary material 2 (avi 897 kb)
430_2019_614_MOESM3_ESM.avi (898 kb)
Supplementary material 3 (avi 899 kb)


  1. 1.
    Spaulding AR, Salgado-Pabón W, Kohler PL, Horswilla AR, Leung YM, Schlievert PM (2013) Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 26(3):422–447. CrossRefGoogle Scholar
  2. 2.
    Phillips JH, Gumperz JE, Arham PP, Lanier LL (1995) Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268(5209):403–405. CrossRefGoogle Scholar
  3. 3.
    Kumar S, Ménoret A, Ngoi SM, Vella AT (2010) The systemic and pulmonary immune response to staphylococcal enterotoxins. Toxins 2(7):1898–1912. CrossRefGoogle Scholar
  4. 4.
    Fraser JD (2011) Clarifying the mechanism of superantigen toxicity. Plos Biol 9(9):e1001145. CrossRefGoogle Scholar
  5. 5.
    Taylor AL, Llewelyn MJ (2010) Superantigen-induced proliferation of human CD4+ CD25− T cells is followed by a switch to a functional regulatory phenotype. J Immunol 185(11):6591–6598. CrossRefGoogle Scholar
  6. 6.
    Reddy PN, Paul S, Sripathy MH, Batra HV (2015) Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model. Toxicon 103:106–113. CrossRefGoogle Scholar
  7. 7.
    Liu Y, Xu M, Su Z, Cai Y, Zhang G, Zhang H (2012) Increased T-cell stimulating activity by mutated SEC2 correlates with its improved antitumour potency. Lett Appl Microbiol 55:362–369. CrossRefGoogle Scholar
  8. 8.
    Yu JY, Tian R, Xiu BS, Yan JQ, Jia R, Zhang L, Chang AE, Song HB, Li Q (2009) Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. Int J Biol Sci 5:135–146. CrossRefGoogle Scholar
  9. 9.
    Hu DL, Nakane A (2014) Mechanisms of staphylococcal enterotoxin-induced emesis. Eur J Pharmacol 722:95–107. CrossRefGoogle Scholar
  10. 10.
    Zhao Y, Zhu A, Tang J, Tang C, Chen J (2017) Identification and measurement of staphylococcal enterotoxin M (SEM) from Staphylococcus aureus isolate associated with staphylococcal food poisoning. Lett Appl Microbiol 65:27–34. CrossRefGoogle Scholar
  11. 11.
    Lina G, Bohach GA, Nair SP, Hiramatsu K, Marche EJ, Mariuzza R (2004) Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 189(12):2334–2336. CrossRefGoogle Scholar
  12. 12.
    Ulett GC, Ketheesan N, Hirst RG (2000) Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect Immun 68:2034–2042. CrossRefGoogle Scholar
  13. 13.
    Halloran PF, Urmson J, Ramassar V, Melk A, Zhu LF, Halloran BP, Bleackley RC (2004) Lesions of T-cell-mediated kidney allograft rejection in mice do not require perforin or granzymes A and B. Am J Transplant 4:705–712. CrossRefGoogle Scholar
  14. 14.
    Seo KS, Park JY, Terman DS, Bohach GA (2010) A quantitative real time PCR method to analyze T cell receptor Vβ subgroup expansion by staphylococcal superantigens. J Transl Med. Google Scholar
  15. 15.
    Khan AA, Martin S, Saha B (2008) SEB-induced signaling in macrophages leads to biphasic TNF-a. J Leukocyte Biol 83:1363–1369. CrossRefGoogle Scholar
  16. 16.
    Krakauer T (2013) Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins 5:1629–1654. CrossRefGoogle Scholar
  17. 17.
    Liu Y, Xu M, Zhang H, Li X, Su ZC, Zhang CG (2013) SEC2-induced superantigen and antitumor activity is regulated through calcineurin. Appl Microbiol Biot 97:9695–9703. CrossRefGoogle Scholar
  18. 18.
    Zhou J, Liu L, Xu M, Zhang HW, Zhang YX, Zhang CG (2013) T-cell proliferation and antitumour activities of a truncated mutant of staphylococcal enterotoxin C2 with decreased cytokine secretion. J Med Microbiol 62:451–456. CrossRefGoogle Scholar
  19. 19.
    Torres BA, Kominsky S, Perrin GQ, Hobeika AC, Johnson HM (2001) Superantigens: the good, the bad, and the ugly. Exp Biol Med 226(3):164–176. CrossRefGoogle Scholar
  20. 20.
    Perabo FG, Willert PL, Wirger A, Schmidt DH, Wardelmann E, Sitzia M, Ruecker A, Mueller SC (2005) Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. Int J Gyneco Cancer 115:591–598. CrossRefGoogle Scholar
  21. 21.
    Wang X, Zhang H, Xu M, Liu CX, Zhang CG (2009) Biological analysis of the deletion mutants of Staphylococcal enterotoxin C2. Appl Microbiol Biot 83:1077–1084. CrossRefGoogle Scholar
  22. 22.
    Kulhankova K, King J, Pabón WS (2014) Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol Res 59:182–187. CrossRefGoogle Scholar
  23. 23.
    Omoe K, Hu DL, Ono HK, Shimizud S, Omoee HT, Nakanec A, Uchiyamaf T, Shinagawaa K, Imanishig K (2013) Emetic potentials of newly identified staphylococcal enterotoxin-like toxins. Infect Immun 81(10):3627–3631. CrossRefGoogle Scholar
  24. 24.
    Orwin PM, Leung DY, Tripp TJ, Bohach GA, Earhart CA, Ohlendorf DH, Schlievert PM (2002) Characterization of a novel staphylococcal enterotoxin-like superantigen, a member of the group Vβ subfamily of pyrogenic toxins. Biochemistry 41(47):14033–14040. CrossRefGoogle Scholar
  25. 25.
    Orwin PM, Leung DY, Donahue HL, Novick RP, Schlievert PM (2001) Biochemical and biological properties of staphylococcal enterotoxin K. Infect Immun 69(1):360–366. CrossRefGoogle Scholar
  26. 26.
    Ding D, Huang P, Pan YQ, Chen SQ (2011) Gene detection of staphylococcal enterotoxins in production strain of staphylococcin injection and superantigenic activity of rSEK and rSEQ. J Microbiol Biotech 27(12):2957–2967. CrossRefGoogle Scholar
  27. 27.
    Hu DL, Ono HK, Isayama S, Okada R, Okamura M, Lei LC, Nakane A (2017) Biological characteristics of staphylococcal enterotoxin Q and its potential risk for food poisoning. J Appl Microbiol 122(6):1672–1679. CrossRefGoogle Scholar
  28. 28.
    Platanias LC (2013) Interferons and their antitumor properties. J Interf Cytok Res 33(4):143–144. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Stem Cell Research Center, College of Life Science and TechnologyXinxiang Medical UniversityXinxiangChina
  2. 2.Henan Key Laboratory of Medical Tissue RegenerationXinxiangChina
  3. 3.College of Biomedical EngineeringXinxiang Medical UniversityXinxiangChina

Personalised recommendations